763 related articles for article (PubMed ID: 23742912)
1. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Berg T; Marcellin P; Zoulim F; Moller B; Trinh H; Chan S; Suarez E; Lavocat F; Snow-Lampart A; Frederick D; Sorbel J; Borroto-Esoda K; Oldach D; Rousseau F
Gastroenterology; 2010 Oct; 139(4):1207-17. PubMed ID: 20600025
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
[TBL] [Abstract][Full Text] [Related]
6. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
Tan J; Degertekin B; Wong SN; Husain M; Oberhelman K; Lok AS
J Hepatol; 2008 Mar; 48(3):391-8. PubMed ID: 18199519
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF.
Liu Y; Fung S; Gane EJ; Dinh P; Flaherty JF; Svarovskaia ES; Miller MD; Kitrinos KM
J Med Virol; 2014 Sep; 86(9):1473-81. PubMed ID: 24861361
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
Berg T; Zoulim F; Moeller B; Trinh H; Marcellin P; Chan S; Kitrinos KM; Dinh P; Flaherty JF; McHutchison JG; Manns M
J Hepatol; 2014 Apr; 60(4):715-22. PubMed ID: 24295873
[TBL] [Abstract][Full Text] [Related]
11. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
12. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
Snow-Lampart A; Chappell B; Curtis M; Zhu Y; Myrick F; Schawalder J; Kitrinos K; Svarovskaia ES; Miller MD; Sorbel J; Heathcote J; Marcellin P; Borroto-Esoda K
Hepatology; 2011 Mar; 53(3):763-73. PubMed ID: 21374657
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
15. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
[TBL] [Abstract][Full Text] [Related]
16. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
[TBL] [Abstract][Full Text] [Related]
17. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
18. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
Menne S; Butler SD; George AL; Tochkov IA; Zhu Y; Xiong S; Gerin JL; Cote PJ; Tennant BC
Antimicrob Agents Chemother; 2008 Oct; 52(10):3617-32. PubMed ID: 18676881
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
20. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
